From Nasdaq: 2025-05-14 08:30:00

Investors looking for opportunities in pharmaceuticals should monitor oversold stocks using the Relative Strength Index (RSI). Sarepta Therapeutics, Krystal Biotech, and Lantheus Holdings are currently at extremely oversold levels. Sarepta’s RSI is at 22, signaling a rebound potential with bullish analyst support for its genetic medicine pipeline and Elevidys drug. Krystal Biotech’s RSI is at 33, showing signs of recovery after a recent sell-off, while Lantheus Holdings’ RSI is at 28, sitting at a long-term support line with strong product offerings. These high-quality pharma stocks present potential upside for investors. 1. The stock market experienced a sharp decline today, with the Dow Jones Industrial Average falling by 500 points. This drop was attributed to concerns about rising inflation and interest rates, as well as uncertainty surrounding global trade tensions.

2. In other news, a new study has found that over 70% of Americans are living paycheck to paycheck. The study also revealed that nearly 40% of people would struggle to cover a $400 emergency expense.

3. On a more positive note, the unemployment rate has dropped to 3.9%, the lowest it has been in 18 years. This decrease was driven by strong job growth in sectors such as manufacturing, healthcare, and professional services.

4. In international news, tensions are escalating between the United States and Iran following President Trump’s decision to withdraw from the Iran nuclear deal. The move has raised concerns about the stability of the region and the potential for increased conflict.



Read more at Nasdaq:: Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore